公司资料
Edesa Biotech Inc. 股价、新闻与催化剂
- 股票代码:
- EDSA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
2.17 USD (+5.58%)
收盘价
最后更新: 2026年11月19日
—
市值
股价为何变动
截至 2026年11月19日,EDSA 上涨 5.58%,收于 $2.17。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Host-Directed Immunology Developer
Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed therapies for inflammatory and immune-mediated diseases. Its pipeline is organized around medical dermatology and respiratory medicine, with programs intended to modify disease-driving immune pathways rather than treat symptoms alone.
EB06 Vitiligo Program
EB06 is a fully human monoclonal antibody that binds CXCL10 and blocks its interaction with the CXCR3A and CXCR3B receptors. Edesa is developing the candidate as a systemic therapy for moderate-to-severe nonsegmental vitiligo, where CXCL10 is implicated in immune-cell trafficking to the skin and melanocyte loss. The ongoing randomized Phase 2 study is evaluating EB06 against placebo in up to 80 adults, with change in the Facial Vitiligo Area Scoring Index at Week 28 as the primary efficacy endpoint.
Paridiprubart Respiratory Program
Paridiprubart is a human monoclonal antibody targeting toll-like receptor 4, a regulator of innate immune signaling. The candidate is being developed for acute respiratory distress syndrome and is also being evaluated in patients with concurrent acute kidney injury. Clinical analyses have associated paridiprubart plus standard care with mortality reductions in respiratory-failure populations, supporting continued regulatory and late-stage development planning.
Daniluromer Dermatology Asset
Daniluromer, formerly EB01, is a 1.0% topical cream developed for moderate-to-severe chronic allergic contact dermatitis. The asset is Phase 3-ready and gives Edesa a second dermatology program alongside the systemic EB06 vitiligo study.
Partnership and Funding Model
Edesa uses partnerships and public-sector support to advance capital-intensive programs. Kyorin Pharmaceutical holds exclusive Japanese rights to develop and commercialize paridiprubart for ARDS, while Edesa retains rights outside Japan and supplies the product. The respiratory program has also received Canadian government funding and is being evaluated in a U.S. government-funded platform study.
未来催化剂
- Initial enrollment at U.S. sites in the Phase 2 EB06 vitiligo study in the first quarter of 2027.
- Topline results from the Phase 2 EB06 vitiligo study in the fourth quarter of 2027.
近期新闻
新闻标题由机器翻译,详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。
